Treatment of latent infection with Mycobacterium tuberculosis: update 2010
Open Access
- 6 August 2010
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 37 (3), 690-711
- https://doi.org/10.1183/09031936.00079310
Abstract
Much remains unknown about latent infection with Mycobacterium tuberculosis. Existing immunodiagnostic tools for this condition have various limitations, most importantly in their ability to predict disease. Randomised controlled trials have established protective efficacy of isoniazid therapy for 6–12 months among non-HIV-infected and HIV-infected subjects. While efficacy may reach 90%, acceptance and adherence to prolonged therapy are less than desired. Rifampicin plus pyrazinamide for 2 months, though efficacious, has been associated with excess hepatotoxicity in non-HIV-infected persons. Isoniazid plus rifampicin for 3 months has proven efficacy, but adverse effects may be more frequent than isoniazid or rifampicin monotherapy. Rifampicin monotherapy for 3–4 months is well tolerated, but efficacy data are currently limited, and concerns remain over possible selection of rifampicin-resistant mutants. For contacts of patients with multidrug-resistant tuberculosis, expert opinions differ on whether to treat with at least two drugs or just a fluoroquinolone, and for how long. With the existing diagnostic and treatment tools, efficacy of preventive therapy does not necessarily translate into field effectiveness. A targeted approach is required to maximise cost-effectiveness. Each geographic region needs to set its own priority after taking into account available scientific data and local circumstances.This publication has 97 references indexed in Scilit:
- The Mycobacterium tuberculosis DosR Regulon Assists in Metabolic Homeostasis and Enables Rapid Recovery from Nonrespiring DormancyJournal of Bacteriology, 2010
- Management of individuals requiring antiretroviral therapy and TB treatmentCurrent Opinion in HIV and AIDS, 2010
- Clinical Characteristics and Treatment Outcomes of Patients with Isoniazid‐Monoresistant TuberculosisClinical Infectious Diseases, 2009
- Impact of the Interaction of R207910 with Rifampin on the Treatment of Tuberculosis Studied in the Mouse ModelAntimicrobial Agents and Chemotherapy, 2008
- The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosisProceedings of the National Academy of Sciences of the United States of America, 2008
- Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- The resuscitation‐promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitroMolecular Microbiology, 2007
- Synergistic Activity of R207910 Combined with Pyrazinamide against Murine TuberculosisAntimicrobial Agents and Chemotherapy, 2007
- A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus InfectionThe New England Journal of Medicine, 1989
- Pyridoxine supplementation during isoniazid therapyTubercle, 1980